AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01963104 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pure-tone Screener/Motivation video
Description: During the test different tones are going to be presented at one volume level. Participants will identify whether or not they heard the tone and receive printed recommendations for hearing healthcare follow-up. They will also watch a brief video that shows how hearing works and learn about the different types of hearing loss. All subjects will complete the Hearing Handicap Inventory (HHI) questionnaire and the Hearing Beliefs Questionnaire (HBQ). Approximately 6-8 months after their initial appointment, subjects in this group will receive a telephone call and will be asked questions related to their actions and attitudes related to hearing and hearing health care.
Study NCT01963104 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Digits-in-noise test/Motivational video
Description: During the test subjects will hear a pattern of 3 numbers with variable noise in the background and identify the pattern they hear, and receive printed recommendations for hearing healthcare follow-up. They will also watch a brief video that shows how hearing works and learn about the different types of hearing loss. All subjects will complete the Hearing Handicap Inventory (HHI) questionnaire and the Hearing Beliefs Questionnaire (HBQ). Approximately 6-8 months after their initial appointment, subjects in this group will receive a telephone call and will be asked questions related to their actions and attitudes related to hearing and hearing health care.
Study NCT01659918 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Singulair
Study NCT01963104 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: No screening test/Motivational video
Description: This group of subjects will not receive a screening test. They will watch a brief video that shows how hearing works and learn about the different types of hearing loss. All subjects will complete the Hearing Handicap Inventory (HHI) questionnaire and the Hearing Beliefs Questionnaire (HBQ). Approximately 6-8 months after their initial appointment, subjects in this group will receive a telephone call and will be asked questions related to their actions and attitudes related to hearing and hearing health care.
Study NCT01963104 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Home Hearing Screening Test
Description: Subjects will be taught the set-up for a home hearing screening test and will take an automated hearing test that presents tones at different pitches and volumes. Participants will identify whether or not they heard the tone and receive printed recommendations for hearing healthcare follow-up. All subjects will complete the Hearing Handicap Inventory (HHI) questionnaire and the Hearing Beliefs Questionnaire (HBQ). Approximately 6-8 months after their initial appointment, subjects in this groups will receive a telephone call and will be asked questions related to their actions and attitudes related to hearing and hearing health care.
Study NCT00671281 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic acid
Description: Oral form, 100mg, tid (three times per day), 3 days before/the day of/6 days after the surgery
Study NCT01963104 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Home Hearing Screening Test/Brief video
Description: Subjects will be taught the set-up for a home hearing screening test and will take an automated hearing test that presents tones at different pitches and volumes. Participants will identify whether or not they heard the tone and receive printed recommendations for hearing healthcare follow-up. All subjects will complete the Hearing Handicap Inventory (HHI) questionnaire and the Hearing Beliefs Questionnaire (HBQ). They will also watch a brief video that shows how hearing works and learn about the different types of hearing loss.~Approximately 6-8 months after their initial appointment, subjects in this groups will receive a telephone call and will be asked questions related to their actions and attitudes related to hearing and hearing health care.
Study NCT03055676 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Early drain removal
Description: Removing drain(s) on postoperative day 3
Study NCT03055676 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Late drain removal
Description: Removing drain(s) on postoperative day 5 or later
Study NCT01578239 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Octreotide LAR
Description: In the experimental arm, 30 mg Octreotide LAR treatment was given to the participants until the end of study for symptom control purpose, unless the participant progressed or died.~In the active comparator arm, 60 mg Octreotide LAR treatment was given to the participants every 4 weeks (i.m. injections) until the end of the study, unless the participant progressed or died.
Study NCT01578239 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Octreotide LAR
Description: In the experimental arm, 30 mg Octreotide LAR treatment was given to the participants until the end of study for symptom control purpose, unless the participant progressed or died.~In the active comparator arm, 60 mg Octreotide LAR treatment was given to the participants every 4 weeks (i.m. injections) until the end of the study, unless the participant progressed or died.
Study NCT01578239 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 177Lu-DOTA0-Tyr3-Octreotate
Description: Four administrations of 7.4 GBq (200 mCi) 177Lu-DOTA0-Tyr3-Octreotate administered at 8 +/- 1-week intervals, which could be extended up to 16 weeks to accommodate resolving acute toxicity.
Study NCT00671281 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, Oral form, three times a day, 3 days before/day of/6 days after surgery
Study NCT00006105 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: amifostine trihydrate
Study NCT00006105 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Study NCT00006105 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride
Study NCT00006105 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: adjuvant therapy
Study NCT00759759 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: morphine sulfate sustained-release capsules
Description: 1 x 200 mg, single-dose capsule
Study NCT01842438 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral: psychosexual intervention
Description: 6 session manualised intervention, This manual-based family-relational-psychosexual support was based on systemic principles combined with techniques from sex therapy, i.e. sensate focus. The manual offered an intermediate level of specificity, enabling practitioners to use their own therapeutic style and take some lead from the couple while meeting the objectives of the intervention. Specialist training in delivery of the intervention was provided to practitioners holding accredited counselling or psychotherapy qualifications. Practitioners engaged in routine clinical supervision with one additional team supervision session offered by one of the practitioners
Study NCT02694822 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGEN1884
Description: anti-CTLA-4 antibody
Study NCT02644954 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Metformin 850 mg twice daily given in the intervention arm to patients of moderate psoriasis
Study NCT02644954 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo drug twice daily given in the intervention arm to patients of moderate psoriasis
Study NCT02644954 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topical Coal tar
Description: Topical coal tar to be applied once daily
Study NCT02644954 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Topical Coal tar
Description: Topical coal tar to be applied once daily
Study NCT02644954 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topical calcipotriol
Description: Topical calcipotriol to be applied once daily
Study NCT02644954 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Topical calcipotriol
Description: Topical calcipotriol to be applied once daily
Study NCT01828502 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education
Description: Participants in both groups will receive education by the EPA on the danger of exposure to secondhand smoke and how exposure can be prevented.
Study NCT01828502 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Education
Description: Participants in both groups will receive education by the EPA on the danger of exposure to secondhand smoke and how exposure can be prevented.
Study NCT01828502 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cotinine Education
Description: Those randomized to the active intervention will also be provided with education utilizing the cotinine test strip in conjunction with the education from the EPA.
Study NCT00759759 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: KADIAN (morphine sulfate sustained-release) capsules
Description: 2 x 100 mg, single-dose capsule
Study NCT02426827 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Spinal Cord Stimulation
Study NCT05161559 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Etching with phosphoric acid gel (3M ESPE, St. Paul, MN, USA)
Description: Etching enamel surface using phosphoric acid gel (3M ESPE, St. Paul, MN, USA)
Study NCT05161559 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Self-etch adhesive (Kuraray, Tokyo, Japan)
Description: No Etching enamel surface using phosphoric acid (self-etch technique) (Kuraray, Tokyo, Japan)
Study NCT05161559 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Chemical bond adhesive (GC, Corporation, Tokyo, Japan)
Description: Chemical bond with hydroxyapatite crystals of Enamel (GC, Corporation, Tokyo, Japan)
Study NCT03850561 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Coenzyme Q10 200
Description: Coenzyme Q10 200 mg/day
Study NCT03850561 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Coenzyme Q10 400
Description: Coenzyme Q10 400 mg/day
Study NCT03525327 — intervention group
Intervention type: OTHER
Intervention: Line Dance Class
Description: Line or party dances to be taught will include:~Electric Slide (Mainland USA)Hukilau (Hawaii)Cupid Shuffle (Mainland USA)Poco Poco (Philippines)Cha Cha Slide (Mainland USA)Tush Push (Mainland USA)Trojan Crawl (Mainland USA)Wobble (Mainland USA)Goyang Maumere (Indonesia)
Study NCT01551394 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Meropenem
Description: 20 mg/kg every 8 hours (every 12 hours in the youngest age group: \< 32 weeks GA and \< 2 weeks postnatal age). The dose will be given as an infusion over 30 minutes. Treatment duration is 11 ± 3 days.
Study NCT03277287 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Fractional CO2 laser
Description: Fractional CO2 laser will be applied in cleft lip scar to assess and evaluate the later appearance of the scar
Study NCT01156753 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CDX-011
Description: CDX-011 (1.88 mg/kg) administered as an intravenous infusion on Day 1 of each 21 day cycle.
Study NCT01156753 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Investigator's Choice chemotherapy
Description: Any of the following single-agent chemotherapy may be given at the discretion of the investigator, with a cycle length not to exceed four weeks: Capecitabine, Vinorelbine, Gemcitabine, Docetaxel, Paclitaxel, Albumin-bound paclitaxel, Doxorubicin HCL, Liposomal doxorubicin, Ixabepilone and Eribulin.
Study NCT01952340 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Flaxseed
Description: Milled flaxseed
Study NCT01952340 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Wheat germ/wheat bran and mixed dietary oils
Study NCT03792594 — intervention group
Intervention type: OTHER
Intervention: arthroscopic repair with bone marrow concentration
Description: arthroscopic repair with bone marrow concentration
Study NCT03792594 — intervention group
Intervention type: OTHER
Intervention: arthroscopic repair
Description: arthroscopic repair only
Study NCT01782131 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Posaconazole
Description: POS IV: Day 1: 300 mg BID Day 2-84: 300 mg QD POS oral: Day 1: 300 mg BID Day 2-84: 300 mg QD
Study NCT01782131 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Voriconazole
Description: VOR IV: Day 1: 6 mg/kg per body weight administered BID Day 2-84: 4 mg/kg per body weight administered BID VOR oral: Day 1: 300 mg BID Day 2-84: 200 mg BID
Study NCT01782131 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo received for Posaconazole (IV and oral) or Voriconazole (oral)
Study NCT01782131 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Matching placebo received for Posaconazole (IV and oral) or Voriconazole (oral)
Study NCT01551394 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ampicillin + gentamicin or cefotaxime + gentamicin
Description: Ampicillin:~Neonates below 7 days: 50mg/kg every 12 hours Neonates 7-21 days: 50mg/kg every 8 hours Neonates and Infants from day 22 on: 50mg/kg every 6 hours~Gentamicin:~Neonates less than 32 weeks of corrected age: 5mg/kg every 36 hours Neonates 32 weeks and over of corrected age: 5mg/kg every 24 hours (pre-dose ('trough') concentrations should be less than 2mg/l) Infants over 28 days of postnatal age: once daily dose: initially 5-7mg/kg, then adjust according to serum-gentamicin concentration (pre-dose ('trough') concentrations should be less than 1mg/l)~Cefotaxime:~Neonates below 7 days of PNA: 50mg/kg every 12 hours Neonates and infants from day 7 of PNA: 50mg/kg every 8 hours Treatment duration is 11 ± 3 days.
Study NCT01115699 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Repetitive Transcranial Magnetic Stimulation (rTMS)
Description: Active 10 Hz rTMS will be applied to the left dorsolateral prefrontal cortex (L-DLPFC) with an intensity of 120% motor threshold. The L-DLPFC location is defined as that area 5 cm anterior to the motor cortex for activation of abductor pollicis brevis. Subjects will receive a total of 3000 stimuli per session. The TMS trains are 4 seconds on and 26 seconds off for a total of 37 1/2 minutes. Treatment will occur 5 days per week for up to six weeks. Subjects will be monitored during rTMS for any side effects or adverse events.
Study NCT03939403 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Time of administration of Corifollitropin Alfa
Description: The used treatment will be identical in both arms. The difference between the groups will be the moment of beginning of the stimulation as well as the later administration of more FSH activity.~The control grup will receive the treatment on the 5th day after the cessation of hormonal contraceptive use. The used treatment will be identical in both arms. The difference between the groups will be the moment of beginning of the stimulation as well as the later administration of more FSH activity.~The intervention grup will receive the treatment on the 7th day after the cessation of hormonal contraceptive use.
Study NCT00817869 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: New flooring
Description: 8.3mm thick vinyl floor covering with foam backing, manufactured by Tarkett and installed by Tyndale Flooring Ltd.
Study NCT01910597 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SBG
Study NCT01067989 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide, Capecitabine, Methotrexate, Celecoxib, Pamidronate (or Zoledronate)
Description: 1. Cyclophosphamide Tab. 50mg, 1x1/day, continuously.~2. Capecitabine Tab. 500mg, 1+2/day, continuously.~3. Methotrexate Tab. 2.5mg, 1x2/day, 2 days every week.~4. Celecoxib Tab. 200mg, 1x2/day, continuously.~5. Pamidronate I.V. 90mg, every 4 weeks; or Zoledronate I.V. 4mg, every 4 weeks)
Study NCT02170142 — intervention group
Intervention type: DEVICE
Intervention: MRI
Description: non-invasive MRI techniques (DTI) and (ASL) will be used to assess normal brain development. DTI is capable of invasively delineating macroscopic anatomic components with high contrast and revealing structures at the microscopic level. ASL is capable of measuring cerebral blood flow and cerebral metabolic rate of oxygen.
Study NCT03159988 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Angiotensin-(1-7)
Description: Angiotensin-(1-7) 100mcg/kg/day for 12 weeks
Study NCT03159988 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Memory Training
Description: 50% of the treatment arm will receive 2 session per week for 2 weeks of memory training
Study NCT00893867 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DP-b99
Description: 1mg/kg/day over 4 consecutive days given intravenously and initiated up to 9 hours following acute stroke onset.
Study NCT00893867 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1mg/kg/day over 4 consecutive days given intravenously and initiated up to 9 hours following acute stroke onset.
Study NCT06289335 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: saline solution
Description: 20 mL of saline
Study NCT06289335 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: saline solution
Description: 20 mL of saline
Study NCT02946619 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-Regulation Condition
Study NCT02946619 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced self-Regulation Condition
Study NCT01508572 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab-IRDye800CW
Description: In this two stage, non-randomized, non-blinded, prospective, multicenter feasibility study, bevacizumab-IRDye800CW will be administered to a total of 20 patients with proven breast cancer.
Study NCT00355680 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Green Laser (Aurolas, Aurolab)
Description: Green laser developed by Aurolab
Study NCT00355680 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Green Laser (Iridex)
Description: Already available green laser
Study NCT04896918 — intervention group
Intervention type: BEHAVIORAL
Intervention: Tobacco use
Study NCT02428634 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PSIE13
Description: The Program SI! is implemented from 1st to 3rd grade of Elementary. A total of 40 hours of intervention on 1st and 2nd grade and 30 hours on 3rd grade has been established as the minimum intervention per year.
Study NCT02428634 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PSIE46
Description: The Program SI! is implemented from 4th to 6th grade of Elementary. A total of 30 hours of intervention has been established as the minimum intervention per year.
Study NCT01408407 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Aveeno cream
Description: Apply cream on irradiated area twice a day
Study NCT01408407 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aveeno cream
Description: Apply cream on irradiated area twice a day
Study NCT01408407 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Alkagin paste
Description: Apply Alkagin paste three times a day.
Study NCT03231709 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trelagliptin
Description: Trelagliptin tablets
Study NCT03231709 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alogliptin
Description: Alogliptin tablets
Study NCT03162016 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: transplants
Description: Transplant of palatine tissue and transplant of connective tissue Mucoderm
Study NCT03162016 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: transplants
Description: Transplant of palatine tissue and transplant of connective tissue Mucoderm
Study NCT01266473 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physiotherapy
Description: Physiotherapy for Airway Clearance
Study NCT00334828 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: eritoran tetrasodium
Description: Intravenous infusion at a total dose of 105 mg.
Study NCT00334828 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo; intravenous infusion.
Study NCT03658356 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Video instructions
Description: Pregnant patient will watch her video explaining how to collect a urine sample for asymptomatic bacteriuria determination.
Study NCT03658356 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Video instructions
Description: Pregnant patient will watch her video explaining how to collect a urine sample for asymptomatic bacteriuria determination.
Study NCT00133094 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Simvastin
Study NCT00133094 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Computer-based decision support technology
Study NCT04509752 — intervention group
Intervention type: OTHER
Intervention: Survey
Description: An online survey will be sent to each clinic to answer the survey questions.
Study NCT03679845 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sarilumab
Description: Sarilumab is an IL-6 monoclonal antibody that has shown to be potentially important in the creation of sclerosis in SSc.
Study NCT00561093 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pentoxiphylline
Description: pentoxiphylline 400 mg daily, anti-inflammatory and appetite-stimulating while subjects undergo thrice weekly hemodialysis and during the following non-dialysis day (6 days per week)